Taysha Gene Therapies (NASDAQ:TSHA) Insider Sukumar Nagendran Sells 89,132 Shares of Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) insider Sukumar Nagendran sold 89,132 shares of Taysha Gene Therapies stock in a transaction on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $423,377.00. Following the transaction, the insider owned 1,344,307 shares in the company, valued at $6,385,458.25. The trade was a 6.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Sukumar Nagendran also recently made the following trade(s):

• On Monday, January 26th, Sukumar Nagendran sold 26,918 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.61, for a total value of $124,091.98.
• On Monday, January 12th, Sukumar Nagendran sold 200,000 shares of Taysha Gene Therapies stock. The stock was sold at an average price of $4.71, for a total value of $942,000.00.
• On Friday, November 28th, Sukumar Nagendran sold 110,125 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total value of $523,093.75.
• On Monday, December 1st, Sukumar Nagendran sold 260,047 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.51, for a total value of $1,172,811.97.

Taysha Gene Therapies Stock Performance

Taysha Gene Therapies stock opened at $4.76 on Wednesday. The firm has a market capitalization of $1.30 billion, a PE ratio of -14.42 and a beta of 1.02. Taysha Gene Therapies, Inc. has a one year low of $1.05 and a one year high of $6.02. The stock’s 50 day moving average price is $5.09 and its 200 day moving average price is $4.08. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. As a group, sell-side analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on TSHA. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price objective on shares of Taysha Gene Therapies in a research note on Friday, November 14th. Wells Fargo & Company raised their price target on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, January 5th. Citigroup restated an “outperform” rating on shares of Taysha Gene Therapies in a research note on Wednesday, November 5th. The Goldman Sachs Group set a $11.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $10.67.

Institutional Trading of Taysha Gene Therapies

Several institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Taysha Gene Therapies by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock worth $73,000 after buying an additional 2,765 shares during the last quarter. Xponance Inc. raised its stake in Taysha Gene Therapies by 29.1% during the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock worth $54,000 after acquiring an additional 3,738 shares during the period. Principal Financial Group Inc. raised its stake in Taysha Gene Therapies by 33.6% during the third quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock worth $53,000 after acquiring an additional 4,091 shares during the period. ST Germain D J Co. Inc. lifted its holdings in Taysha Gene Therapies by 81.8% in the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after acquiring an additional 4,333 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Taysha Gene Therapies by 25.8% in the third quarter. Legal & General Group Plc now owns 23,149 shares of the company’s stock valued at $76,000 after acquiring an additional 4,754 shares during the period. Institutional investors own 77.70% of the company’s stock.

Trending Headlines about Taysha Gene Therapies

Here are the key news stories impacting Taysha Gene Therapies this week:

• Negative Sentiment: CFO Kamran Alam sold 78,968 shares on Jan. 23 at ~$4.75 and 23,849 shares on Jan. 26 at ~$4.61 (total ≈102,817 shares, ≈$485k). This reduced his stake by about 5.11% and 1.62% in the respective filings. CFO Form 4
• Negative Sentiment: CEO Sean P. Nolan sold 136,789 shares on Jan. 23 at ~$4.75 and 41,312 shares on Jan. 26 at ~$4.61 (total ≈178,101 shares, ≈$840k). These sales reduced his ownership by ~4.43% and ~1.40% in the respective filings. CEO Form 4
• Negative Sentiment: Insider Sukumar Nagendran sold 89,132 shares on Jan. 23 at ~$4.75 and 26,918 shares on Jan. 26 at ~$4.61 (total ≈116,050 shares, ≈$547k), reducing his stake by ~6.22% and ~2.00% in the respective filings. Director Form 4

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.